Trial Profile
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs INBRX 109 (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Irinotecan; Pemetrexed; Temozolomide
- Indications Adenocarcinoma; Chondrosarcoma; Colorectal cancer; Ewing's sarcoma; Gastric cancer; Malignant-mesothelioma; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Inhibrx
- 01 Feb 2024 Planned End Date changed from 1 Dec 2024 to 1 Jul 2026.
- 01 Feb 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Dec 2025.
- 02 Nov 2023 According to an Inhibrx media release, data from the study were presented at the Annual Connective Tissue Oncology Society (CTOS) Conference today.